Eli Lilly And Co (NYSE:LLY) was the recipient of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 11,188,263 shares, a drop of 26.5% from the October 15th total of 15,215,133 shares. Based on an average daily volume of 4,142,975 shares, the days-to-cover ratio is currently 2.7 days. Approximately 1.2% of the company’s stock are short sold.

Several analysts have issued reports on the company. ValuEngine raised Eli Lilly And Co from a “hold” rating to a “buy” rating in a research note on Monday. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b+” rating in a research note on Tuesday, November 6th. Societe Generale set a $106.00 price target on Eli Lilly And Co and gave the company a “hold” rating in a research note on Wednesday, November 7th. Credit Suisse Group raised Eli Lilly And Co from an “underperform” rating to a “neutral” rating in a research note on Wednesday, October 31st. Finally, Wolfe Research initiated coverage on Eli Lilly And Co in a research note on Tuesday, October 23rd. They issued a “market perform” rating and a $119.00 price target on the stock. Eight analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Eli Lilly And Co presently has an average rating of “Buy” and an average target price of $111.19.

NYSE:LLY opened at $112.39 on Wednesday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.53 and a current ratio of 1.91. The stock has a market capitalization of $118.87 billion, a P/E ratio of 26.26, a P/E/G ratio of 1.79 and a beta of 0.29. Eli Lilly And Co has a 52-week low of $73.69 and a 52-week high of $116.61.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.04. The business had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. Eli Lilly And Co’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.05 earnings per share. On average, analysts anticipate that Eli Lilly And Co will post 5.57 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a yield of 2.00%. The ex-dividend date is Wednesday, November 14th. Eli Lilly And Co’s payout ratio is currently 52.57%.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 6,000 shares of Eli Lilly And Co stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $106.31, for a total value of $637,860.00. Following the sale, the senior vice president now owns 55,224 shares of the company’s stock, valued at approximately $5,870,863.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 190,000 shares of Eli Lilly And Co stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $105.42, for a total value of $20,029,800.00. Following the completion of the sale, the insider now directly owns 119,970,804 shares in the company, valued at approximately $12,647,322,157.68. The disclosure for this sale can be found here. Insiders sold a total of 1,927,900 shares of company stock worth $140,523,795 in the last three months. Company insiders own 0.11% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. FMR LLC grew its holdings in Eli Lilly And Co by 172.9% during the second quarter. FMR LLC now owns 1,188,301 shares of the company’s stock worth $101,398,000 after purchasing an additional 752,864 shares during the period. We Are One Seven LLC bought a new position in Eli Lilly And Co during the third quarter worth about $1,084,000. Greenleaf Trust grew its holdings in Eli Lilly And Co by 37.7% during the second quarter. Greenleaf Trust now owns 9,815 shares of the company’s stock worth $838,000 after purchasing an additional 2,686 shares during the period. First American Bank bought a new position in Eli Lilly And Co during the third quarter worth about $7,863,000. Finally, Peoples Financial Services CORP. grew its holdings in Eli Lilly And Co by 4.7% during the third quarter. Peoples Financial Services CORP. now owns 16,825 shares of the company’s stock worth $1,806,000 after purchasing an additional 750 shares during the period. Institutional investors and hedge funds own 76.19% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/eli-lilly-and-co-lly-short-interest-down-26-5-in-october/2607426.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Trading Penny Stocks

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.